Daren J Austin and Ann Allen
Meta analysis and clinical trial simulation in drug development.
|
J Aluri, B Zussman, J Sidhu, B Patel and D Boyle
Cilomilast (Ariflo): Population pharmacokinetic modeling and validation in COPD patients.
|
Roy Anderson
Patient adherence and the evolution of resistance to anti-viral agents
|
James B. Bassingthwaighte
Developing Integrated Cell Systems
|
A. Bertoldo, G. Sparacino, C. Cobelli
Population approaches for quantitative PET imaging
|
Robert Bies (1,2), Mark E. Sale (3), Bruce G. Pollock (1,2)
Comparing binary tree and automated machine learning covariate search strategies
|
A.Blesius (1), S. Chabaud (1), M. Cucherat (1), P. Mismetti (2), JP. Boissel (1), P.Nony (1).
Potential consequences of drug non-compliance on the therapeutic / iatrogenic effects of oral anticoagulant therapy : an in silico study.
|
Y Bourhis (1), A Iliadis (2), C Lucas (3), AB Depouilly (3), C Laveille (3), B Tranchand (1)
Population Pharmacokinetic Study of Fotemustine
|
K. Brendel(1), M. Legrand(2), A.M. Taburet(3), G. Baron(1), C. Goujard(4), F. Mentré(1) and the Cophar-1 study group.
Population pharmacokinetic analysis of indinavir in HIV-patients treated with a stable antiretroviral therapy
|
Sophie Callies 2, Dinesh P de Alwis 1, Michael Burgess 1, and Leon Aarons 2
Pharmacokinetics of Daunorubicin and its metabolite Daunorubicinol in the absence and presence of a potent P-gp inhibitor, Zosuquidar.3HCl (LY335979).
|
Pascal Chanu (1), Audrey Janoly-Dumenil (2), Nathalie Bleyzac (2), Jacques Bourgeois (3), Brigitte Tranchand (1)
Pharmacokinetic model for vancomycin performed with sparse data on neonates
|
Sunny Chapel, PhD, Jeffrey S. Barrett, PhD, Marc Pfister, MD
Modeling & Simulation Approach to Discriminate True Food Effects: Comparison with Standard Noncompartmental Methods
|
Xuejun Chen, Suresh Mallikaarjun, Steven L. Bramer
Comparison of different approaches for the analysis of drug exhibiting nonlinearity of Cmax to increasing doses
|
Emmanuelle Comets(1, 3), Kazumasa Ikeda(2), Yusuke Tanigawara(3)
Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients
|
Eugène Cox (1), Henrik Agerso (2), Thomas Senderovitz(2).
A Population Pharmacokinetic-Pharmacodynamic Model For Count Data: Application to the Effect of Atosiban on Uterine Activity in Preterm Labor Patients
|
Milly E de Jonge(1), Alwin DR Huitema(1), Sjoerd Rodenhuis(2) and Jos H Beijnen(1).
Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
|
Willem DeWinter(1), Joost DeJongh(1), Bart Ploeger(1), Richard Urquhart(2), Ian Moules(2), David Eckland(2), and Meindert Danhof(1)
Disease progression modelling; application of population analysis to distinguish between symptomatic and protective treatment effects.
|
Duffull SB (1), Isbister GK (2), Dawson AH (2), Hackett LP (3), Whyte IM (2).
Estimating population pharmacokinetic parameters when dose and dose-time are not known accurately
|
Jan Freijer, Teun Post, Bart Ploeger, Joost DeJongh, Meindert Danhof
Modelling of drug absorption as a transport-limited process
|
T. Funaki(1), Y. Gao(2), R. Wada(2), K. Nakai(1), K. Miura(1), H. Kinoshita(1)
Computer-Assisted Trial Design (CATD) for PEG-IFN with Using PD Marker to Predict Efficacy
|
C. Garnett (1), K.H. Liesenfeld(2), C. Tillmann(2), I. Troconiz(3), H.G. Schaefer(2), J. Stangier(2), H. Lee (1)
Clinical Trial Simulation of the Dose-Response Relationship of a Direct Thrombin Inhibitor, Dabigatran Etexilate, in Hip Replacement Patients
|
MJ. Garrido(1), JM. Cendrós(2), IF. Trocóniz(1), C. Segura(1), C. Peraire(2), R. Obach(2)
Population pharmacokinetic/pharmacodynamic modelling of the haematological effects of the new anticancer drug diflomotecan: A combined analysis from the first two phase I studies
|
Leonid Gibiansky (1), Michel MRF Struys (2), Ekaterina Gibiansky (3)
Simultaneous Population Pharmacokinetic Model of AQUAVAN™ And AQUAVAN™-Derived Propofol
|
Ekaterina Gibiansky (1), Michel MRF Struys (2), Leonid Gibiansky (3)
Bispectral Index of AQUAVAN™-Derived Propofol: Population PK/PD Modeling and Application to an Effect - Controlled Trial
|
William R. Gillespie
Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial
|
P. Girard, L. Claret, W. Ebling and S.T. Forgue, M. Heathman, A. Ghosh, C.T. Benson
Evaluation Of An Osteoporosis Biomarker Model For Simulation Using Posterior Predictive Check Technique
|
S. Gisbert, I. Gueorguieva, L. Aarons and M. Rowland
Incorporating Variability in WBPBPK Models: Application to Three Benzodiazepines with Extrapolation from Rat to Man
|
Sophie Glatt, Mauro Buraglio, Eliane Fuseau
Population Pharmacokinetics of onercept in healthy subjects.
|
Bruce Green(1), John Atherton(2), Justin Westhuyzen(2),Leeanne Kluver(2),David Saltisi(2)
Development of a dosing strategy for enoxaparin in patients with renal impairment using a population pharmacokinetic approach
|
Andreas Groth & Mikael Thomsen
Markedly different predictions about insulin PharmacoDynamic (PD) measurement feasibility in healthy subjects from recently proposed IntraVenousGlucoseToleranceTest (IVGTT)-based insulin-glucose models
|
I. Gueorguieva, L. Aarons, T. Rodgers and M. Rowland
D-Optimal Design for Multivariate Response: Prospective Planning of a Beta-blocker Study in Rat Involving Cassette Dosing
|
N. Hayashi(1), K. P. Zuideveld(1), P. Jordan(2), R. Gieschke(1)
A Mechanism-Based PK/PD Model Predicts the Time-Course of Hematological responses for Epoetin beta
|
Brunhild Schiltmeyer1, Joachim Boos1, Matthias Schwab2, Thomas Mürdter2, Thomas Klingebiel3, G. Fleischhack5, Josef Vormoor1, Bernd Gruhn4 and Georg Hempel1
Population Pharmacokinetics of Intravenous Busulfan in Children
|
Kristin Cecilie Carlsson(1), Heidi Hansen(1), Roger Jelliffe(2), Nils Ove Hoem(3).
Establishing a tool for individualised dosing of gabapentin - The use of a non-parametric population kinetics model in the MM-USCPACK software, a new tool for clinical dosage optimization.
|
Nicholas H.G. Holford 1, Jogarao V.S. Gobburu,2 Diane R. Mould 3
Implications of Including and Excluding Correlation of Random Effects in Hierarchical Mixed Effects Pharmacokinetic Models
|
A.C. Hooker, M. Dodds, and P. Vicini
Simultaneous Population D-Optimal Designs of Pharmacokinetic-Pharmacodynamic Experiments
|
C. Hu, J.Y. Kim, K.H.P. Moore, M.E. Sale
A Modeling Approach to Assessing Bioequivalence (BE) with Presence of Sparsely Sampled Subjects
|
Dymphy Huntjens, Magret Blom-Roosemalen, David Spalding, Meindert Danhof and Oscar Della Pasqua
Modelling of biomarker response of naproxen in rats and humans
|
C. Jamois(1,2,3), E. Comets(3), L. Bonhomme-Faivre(1,2) and F. Mentré(3).
Pharmacokinetic analysis of paclitaxel administered per os in Swiss mice after a pre-treatment with recombinant interleukin-2 (rIL2).
|
Katarina Jelic, Morten Colding-Jørgensen
Obesity and Insulin Resistance: A Fat Link
|
Daniël M. Jonker (1,2), Rob A. Voskuyl (1,2) and Meindert Danhof (1)
Population pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination
|
Fredrik Jonsson and Niclas Jonsson
A pharmacodynamic model for Scandinavian Stroke Scale data
|
Kristin Karlsson, Mats O. Karlsson, Anders Grahnén and E. Niclas Jonsson
Randomized dose ranging trials; assessment of statistical power for various design and analysis strategies
|
T. Kerbusch (1,2), U. Wählby (2), A. Skerjanec (3), P.A. Milligan (1), M.O. Karlsson(2)
Assessment of the in vivo relative potency of the hydroxylated metabolite of darifenacin for the reduction of salivary flow using a population pharmacokinetic-pharmacodynamic meta-analysis
|
In-Sun Nam and Leon Aarons
Multiple Imputation of Serum Creatinine
|
K. Kowalski (1), M. Hutmacher (2)
Evaluation of a Random Sparse Sampling Design: An Assessment of Power and Bias Using Simulation
|
L. Labbé (1), S.M. Hammer (2), J.W. Mellors (3), S. Rosenkranz (4), L.B. Sheiner (1), and the ACTG 398 study team
A Markov Model For The Effect Of Covariates Including Drug Adherence On Longitudinal Viral Response In HIV Patients
|
Estelle Kuhn and Marc Lavielle
Maximum likelihood estimation in nonlinear mixed effects models
|
C. Le Guellec, F. Odoul, A. Henrot, G. Paintaud, E. Saliba, M.-C. Saux, E. Autret-Leca
Population pharmacokinetics of cisapride in preterm and term neonates
|
Nerea Leal(1), Monica Rodriguez(1), Rosario Calvo(1), Fatima Agrad(1), Leire de la Fuente(2), Elena Suarez(1), John C Lukas(3)
Altered effect and pharmacokinetics of propofol in rats with experimental diabetes mellitus
|
Robert Leary [1], Roger Jelliffe [2], Alan Schumitzky[2], Michael Van Guilder [2]
Improved Computational Methods for Statistically Consistent and Efficient PK/PD Population Analysis
|
A. Lemenuel-Diot(1), N.frey(2), C. Laveille(2), R. Jochemsen(2), A. Mallet(1)
Comparison between Gauss Hermite quadrature and NONMEM on the ability to detect subpopulations
|
Lars Lindbom
Parallel computing under Linux
|
Philip J. Lowe (1) and William Sallas (2)
Probabilistic Risk Assessment Using Integrated Preclinical-Clinical PK/PD Modelling in NONMEM
|
Hugo Maas, Oscar Della Pasqua, Meindert Danhof
A hidden markov model for characterizing the anti-migraine action of triptans
|
Delphine Martin, Roeline Jochemsen , Christian Laveille and Nicolas Frey
Combined-PK-Analysis of a new compound exhibiting highly variable plasma profiles due to first pass metabolism
|
B Mc Hugh (1), R Gieschke (1), M Karlsson (2)
Population Pharmacodynamic Analysis of Glucose and Insulin levels Evaluated with a Hot Glucose Minimal Model, a Total Glucose Minimal Model, and an Insulin Minimal Model
|
Y. Merlé (1,2), J.M. Tréluyer (2,3), E. Rey (3), J. Dimet (3), G. Leleu (4), S. Blanche (5).
Nonparametric population analysis of stavudine pharmacokinetic data in neonates, infants, children and adults
|
Miller R, Kowalski KG, Liu J, Frame B, Burger PJ, Corrigan BW, Bockbrader HN, Lalonde R.
Pregabalin Exposure-Adverse Event Analysis in Patients With Neuropathic Pain, Generalized Anxiety Disorder, or Partial Seizures
|
Hussain Mulla, Suneel Pooboni, David Jenkins, Graham Lawson, Richard Firmin, David Upton
Population Pharmacokinetics of Vancomycin during Extra Corporeal Membrane Oxygenation (ECMO)
|
Nguyen T. X. Q.(1), Munafo A. (1), Goggin T. (1)
Population pharmacokinetic modelling of Emfilermin in healthy postmenopausal women and in women undergoing Embryo Tranfer (ET)
|
Gianluca Nucci and Roberto Gomeni
Comparison of alternative models for the analysis of drug disposition profiles showing enterohepatic circulation using a population approach
|
Gianluca Nucci and Roberto Gomeni
Design and power PK/PD experiments using very sparse data
|
K.Ogungbenro and L. Aarons
Sample Size Calculation based on Confidence interval for Pharmacokinetic Studies
|
Xavière Panhard, France Mentré
Evaluation by simulation of tests based on non-linear mixed-effects models in interaction and bioequivalence cross-over trials
|
Vladimir Piotrovsky
Population PK-PD analysis of cardiovascular effects of non-cardiovascular drugs with the emphasis on QT prolongation
|
M. Simeoni(1), F. Fiorentini (2), M. Germani(2), I. Poggesi(2), M. Rocchetti (2)
Application of population approaches in pharmaco-toxicological studies
|
P. Magni(1), R. Bellazzi (1), G. De Nicolao(1), M. Simeoni(1), M. Germani(2), I. Poggesi(2), M. Rocchetti (2)
A Bayesian approach to non-parametric AUC estimation in population studies
|
Lorraine D. Ralph1,2, Alison H. Thomson1,3, Nicola A. Dobbs4, Chris Twelves5
Bayesian Estimation of Epirubicin Clearance by Limited Sampling
|
D.M. Reith (1), W. Hooper (2), M Franklin (2).
Comparison of NONMEM with the Two-Stage approach for obtaining population means of the pharmacokinetic parameters of fluoxetine
|
Jakob Ribbing and Niclas Jonsson
Power, Selection Bias And Predictive Performance Of The Population Pharmacokinetic Covariate Model
|
Monica Rodriguez(1), Nerea Leal(1), Rosario Calvo(1), Elena Suarez(1), Ignacio Ortega(1), John C Lukas(2)
Influence of high levels of alpha-1-acid glycoprotein in the pharmacokinetics and the analgesic effect of methadone in the rat: A population approach
|
M. C. Rosario (1), P. Jacqmin (2), Pat Dorr(1), Manos Perro (1) & Elna van der Ryst (1)
A PK-PD-disease model to support the design of clinical trials of drugs for the treatment of HIV
|
A. Rousseau, F. Saint-Marcoux, J. Debord, P. Marquet.
Pharmacokinetics of cyclosporine in lung transplant patients with and without cystic fibrosis. A NONMEM analysis.
|
Sabrina Salhi and Roberto Gomeni
Population Whole Body Physiologically based Pharmacokinetic/Pharmacodynamic modelling in drug development: Impact of input parameters variability and incertainty on pharmacodynamic response
|
Mark Sale
Applications of Distributed computing in Drug development
|
Sandström M (1), Lindman H (2) , Nygren P (2), and Karlsson MO (1)
Population Analysis of the Pharmacokinetics and the Haematological Toxicity of the Fluorouracil-Epirubicin-Cyclophosphamide Regimen in Breast Cancer Patients
|
Ulrika S.H. Simonsson, Thomas Senderovitz and Mats O. Karlsson
Population PK/PD Modeling of Testosterone (T), LH and Dihydrotestosterone (DHT) Response to Single SC Degarelix in Male Volunteers
|
Joachim Stangier, Karl-Heinz Liesenfeld, Christiane Tillmann, Inaki Troconiz (#), Hans Guenter Schaefer
Population pharmacokinetics/-dynamics of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing hip replacement
|
C.Tillmann, I.F. Trocóniz (#), J. Stangier, K. H. Liesenfeld, H.G. Schaefer
Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR1048) in patients undergoing primary elective total hip replacement surgery.
|
K.H. Liesenfeld, C. Tillmann, I. Troconiz (#), H.G. Schaefer, J. Stangier
Population pharmacodynamic analysis of dabigatran, the active form of the new oral direct thrombin inhibitor dabigatran etexilate (BIBR 1048), on the prolongation of aPTT and ECT in orthopaedic patients.
|
Sy SK(1,2,3), Pieniaszek HJ(3,4), Kornhauser DM(3), Davidson AF(3), Jiao Q(3), Cain V(3,5), Martin DE(3,6)
Pharmacodynamic drug interaction of roxifiban during CYP induction and inhibition
|
Christoffer W. Tornøe(1), Henrik Agersø(1), Henrik A. Nielsen(2), Henrik Madsen(2), and E. Niclas Jonsson(3)
Population Pharmacokinetic Modelling of a Subcutaneous Depot for GnRH Antagonist Degarelix
|
Christoffer W. Tornøe(1), Henrik Agersø(1), E. Niclas Jonsson(2), Henrik Madsen(3), and Henrik A. Nielsen(3)
Non-Linear Mixed-Effects Models in NLME with Differential Equations
|
Karin Tunblad, Margareta Hammarlund-Udenaes and Niclas Jonsson
An integrated model for data from a microdialysis experiment
|
MR, Ballester, MJ Barbanoj, R Antonijoan, M Yritia, M Valle.
Absorption and plasma kinetics of multiple high oral doses of glucose: influence of glibenclamide.
|
An Vermeulen Ph.D., Vladimir Piotrovsky Ph.D.
Modeling the longitudinal concentration-response data after i.m. administration of Risperdal CONSTATM in psychotic patients of different phenotypes
|
Sandra A.G. Visser(1), Susanna Pozarek(1), Tomas Forsberg(2), Johan Gabrielsson(1).
Modelling of the tolerance, rebound and carry-over phenomena observed in clomethiazole-induced hypothermic effects in rats.
|
B. Vrijens(1-2), S.L. Mayer(1),R.Rode(3), R. Bertz(3), J. Urquhart(1)
Dose-Timing Information Improves The Clinical Explanatory Power Of Data On Patient Adherence To Antiretroviral Drug Regimens
|
T. Waterhouse (1), J. Eccleston (1), S. Duffull (2)
Optimal Designs For Parameter Estimation And Model Discrimination
|
Gudrun Würthwein (1), Georg Hempel (2), Felice C. Adler-Shohet (3), Jay M. Lieberman (3), Thomas J. Walsh (4), and Andreas H. Groll (2)
Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates
|
Zamacona MK, Gomeni R
Influence of study design and interindividual variability on In Vitro - In Vivo Correlation evaluation
|
Stefano Zamuner and Roberto Gomeni
Impact of slow receptor binding kinetics and change in Cerebral Blood Flow in receptor occupancy estimation with PET experiments. A simulation study
|
